Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

AstraZeneca

The sale comes after shares in COVID-19 vaccine maker Moderna soared fivefold in 2020.

AstraZeneca sold its stake in Moderna for more than $1 billion last year

British-based drugmaker AstraZeneca plc (NASDAQ: AZN) has sold its 7.7% stake in Moderna Inc. (NASDAQ: MRNA) for more than $1 billion, the Times reported Sunday. What Happened: AstraZeneca disposed of its stake in Moderna following the U.S. biotechnology company's coronavirus vaccine breakthrough, according to the Times report.

AstraZeneca Divests Entire 7.7% Stake In Moderna For $1B: The Times

AstraZeneca Plc has sold its stake in Moderna Inc for more than $1 billion after the American biotechnology company's shares soared on the back of its coronavirus vaccine breakthrough, The Times reported.

Astrazeneca has sold its stake in Moderna for more than $1 billion: The Times

Fulgent Genetics

Teladoc

All three of these stocks have had incredible spikes because of COVID-19. One stock, however, is a safer and stronger long-term investment.

What's the Strongest Buy: Moderna, Teladoc Health, or Fulgent Genetics?

Moderna (NASDAQ: MRNA) saw its stock jump on Thursday despite mounting losses, after the COVID-19 vaccine-maker reported more than double the revenue Wall Street predicted. Moderna missed EPS expectations with revenue far surpassing analyst forecasts as the company first began to recognize revenue from sales of its COVID-19 vaccine in December 2020.

Moderna Misses Expectations But Remains Optimistic For Future Vaccine Rollout

Moderna released its Q420 and FY20 results Feb. 25 - total revenue in FY20 was $803m, net loss was $747m, R&D expenses $1.37bn, and cash position $5.3bn. Frankly, the financials were not the real story - it will take 3-4 more earnings quarters before Moderna reports vaccine earnings in a meaningful way.

Moderna: $18 Billion Advance Purchase Orders In FY2021 Barely Moves Share Price, But Still A Buy

Pacific Biosciences of California

Pfizer

The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.

Coronavirus Mutations: Why The Battle Against Covid Is Just Beginning

Alexion Pharma

Activision Blizzard

Cisco Systems

Mondelez

T-Mobile US

The Nasdaq dropped 3.52% on Feb 25 for its worst session since October on rising rate worries. However, some stocks still remained in the green on that day or lost little.

Nasdaq ETF's Worst Day Since October: Stocks That Survived

Oppenheimer's Hartaj Singh believes the stock's market capitalization is headed to at least $100 billion.

Moderna's Market Value Set to Rise by at Least 75%, Says Noted Analyst

Domino's Pizza

NVIDIA

Best Buy

Nvidia, Moderna, Domino's Pizza and Best Buy were our top stock trades for Friday. Now, let's look at what the charts are trying to tell us.

4 Top Stock Trades for Friday: MRNA, DPZ, BBY, NVDA

Shares of Moderna soared as high as 10% on Thursday after the biotech company revealed fourth-quarter sales that were more than double Wall Street estimates. The company also revealed a forecast of $18.4 billion in Covid-19 vaccine sales for 2021. Shares of the drugmaker pared earlier gains to close at $148.38, up about 2.5%. The Cambridge, Massachusetts-based company reported a loss of $0.69 a share on sales of $570.7 million, double the $0.34 a share on sales of $279.4 million that analysts polled by FactSet expected.

Moderna climbs as 4th-quarter sales blow past expectations and 2021 forecasts surge

Moderna, Inc. (MRNA) CEO Stéphane Bancel on Q4 2020 Results - Earnings Call Transcript

Better than expected revenues will push US firm founded in 2010 into profit for first time

Moderna forecasts $18bn in sales of Covid vaccine this year

Moderna (MRNA) records product sales for the first time which comprises sales of its coronavirus vaccine, mRNA-1273. Stock up.

Moderna (MRNA) Misses on Q4 Earnings, Eyes $18B in Vaccine Sales

Wayfair

While jobless claims fell on weather-related issues, Durable Goods were up big for January.

Jobless Claims, Q4 GDP Dip; Durable Goods Soar +3.4%

Here's a closer look at why you might want to buy the leader in mRNA pharmaceuticals.

1 Green Flag for Moderna Stock

And it will soon soar even more thanks to the strong demand for Moderna's COVID-19 vaccine.

No Surprise Here: Moderna's Revenue Skyrockets in Q4

Moderna (MRNA) delivered earnings and revenue surprises of -176.00% and 74.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Reports Q4 Loss, Tops Revenue Estimates

GameStop

Plug Power

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Here's Why Moderna, Plug Power, AMC, GameStop Are Moving

Moderna, a forerunner in the development of coronavirus vaccines, has the potential to reach a $100 billion-plus market capitalization, according to an analyst.

$100 billion market cap is the blue-sky scenario for Moderna, analyst says

The biotech also reported revenues of $570.7 million in the third quarter of 2020, beating Wall Street expectations.

Moderna's Chief Medical Officer Will Depart This Fall

Moderna stock jumped early Thursday after the Covid-19 vaccine-maker reported more than double the sales that Wall Street analysts expected, though the company's losses grew. The post Moderna Stock Pops On Massive Sales Beat Despite Growing Losses appeared first on Investor's Business Daily.

Moderna Stock Pops On Massive Sales Beat Despite Growing Losses

Apple

AbbVie

Amazon

Gilead Sciences

Microsoft

Zoom Video

As leading biotechs focus on coronavirus tests, vaccines and a potential cure, top stocks and the economy try to rebound. Follow the coronavirus news here.

Coronavirus News: Stock Market, Economy Continue Coronavirus Rebound

BioNTech SE

Moderna, Inc. (NASDAQ:MRNA) said it expects to make US$18.4bn (£13bn) in revenue this year as governments worldwide have booked millions of doses of its COVID-19 vaccine. In 2020, total revenue rocketed 93% to US$803mln, mostly due to grants by the US government to speed up the development of the jab.

Coronavirus: Moderna forecasts US$18.4bn sales this year, Pfizer/BioNTech vaccine proved highly effective by study on 1.2mln people

Moderna also said its chief medical officer, Tal Zaks, will leave the company in late September.

News for Moderna Stock (MRNA)